CNS-5161

CNS-5161
Clinical data
Other namesCNS5161
Routes of
administration
Intravenous, transdermal
Drug classNMDA receptor antagonist; Dissociative; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Elimination half-life2.95 hours
Identifiers
  • 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H18ClN3S2
Molar mass351.91 g·mol−1
3D model (JSmol)
  • CN(C1=CC(=CC=C1)SC)C(=NC2=C(C=CC(=C2)SC)Cl)N
  • InChI=1S/C16H18ClN3S2/c1-20(11-5-4-6-12(9-11)21-2)16(18)19-15-10-13(22-3)7-8-14(15)17/h4-10H,1-3H3,(H2,18,19)
  • Key:JHVHEDNLONERHY-UHFFFAOYSA-N

CNS-5161 is an NMDA receptor antagonist which was under development for the treatment of neuropathic pain and cancer pain but was never marketed. It is taken by intravenously or transdermally.

Adverse effects

CNS-5161 was found to produce mild dissociative-like effects such as visual disturbances and derealization at assessed doses of 250 to 2,000 μg intravenously in clinical trials. In addition, it produced pronounced and dose-limiting hypertension.

Pharmacology

Pharmacodynamics

CNS-5161 is a highly potent and selective noncompetitive antagonist of the NMDA receptor via the ion channel or dizocilpine (MK-801) binding site, with an affinity (Ki) of 1.8 nM. It produces analgesic, anticonvulsant, and neuroprotective effects in rodents. There was also some dose-dependent mortality related to respiratory failure in rodents.

Chemistry

Synthesis

The chemical synthesis of CNS-5161 and isotopologues has been described.

Development

CNS-5161 was under development by CeNeS Pharmaceuticals. It reached phase 2 trials prior to the discontinuation of its development.

See also